Related Experiment Video
Updated: Aug 12, 2026

Mesenchymal Stromal Cell Culture and Delivery in Autologous Conditions: A Smart Approach for Orthopedic Applications
Published on: December 8, 2016
Hematopoietic growth factors in autologous bone marrow transplantation
1Department of Medicine, College of Medicine, University of Florida, Gainesville.
Abstract:
The availability of recombinant human hematopoietic growth factors (rhHGFs) for clinical use has the potential to significantly decrease the morbidity and cost of autologous bone marrow transplantation (ABMT) and to make this therapeutic modality available to a broader patient population. Three rhHGFs currently have Food and Drug Administration-approved indications, although only one has a specific indication for ABMT. Recombinant human granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor have been used in several trials of ABMT. Recombinant human erythropoietin is less well studied to date in the setting of ABMT. Several investigational rhHGFs, including interleukin-3, -6, and -11, PIXY 321 (a granulocyte-macrophage colony-stimulating factor/interleukin-3 hybrid), and kit ligand (also known as "stem cell factor"), have the potential for affecting multiple lineages.
Related Concept Videos
Multipotency of Hematopoietic Stem Cells
Regulation of Hematopoietic Stem Cells
Stem Cell Therapy for Tissue Regeneration
Types of Stem Cells used in Stem Cell Therapy
The two main cell types that...
Overview of Hematopoiesis
Developmental Phases of Hematopoiesis
Initially, HSCs are formed in the embryonic yolk sac, a critical site for early blood cell production. These stem cells subsequently migrate to other...
Role of Hematopoietic Growth Factors
Thrombopoietin (TPO), mainly released by the liver,...
Bone Marrow Sampling and Transplants
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...

